INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE

The present invention relates to the preventive and therapeutic uses of acid sphingomyelinase inhibitors (FIASMAs) such as psychotropic medications and non-psychotropic compounds having FIASMA activity, for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 12. Okt. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

HOERTEL NICOLAS [VerfasserIn]
LIMOSIN FREDERIC [VerfasserIn]
SANCHEZ RICO MARINA LUCIA [VerfasserIn]
ABELLAN MIRIAM [VerfasserIn]
DE LA MUELA PEDRO [VerfasserIn]
GULBINS ERICH [VerfasserIn]
KORNHUBER JOHANNES [VerfasserIn]
CARPINTEIRO ALEXANDER [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-10-12, Last update posted on www.tib.eu: 2023-11-16, Last updated: 2023-11-24

Patentnummer:

US2023321008

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA018295185